July 15th 2025
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.
Adding HIPEC to Cytoreductive Surgery Does Not Impact HRQOL in Ovarian Cancer
March 25th 2023Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.
Niraparib Maintenance Demonstrates Favorable OS Trend in Platinum-Sensitive Recurrent Ovarian Cancer
December 29th 2022Findings from the phase 3 NORA study identified a numerically longer median overall survival among patients with platinum-sensitive recurrent ovarian cancer treated with maintenance niraparib regardless of BRCA mutation status.
FDA Grants Fast Track Designation to Novel HSF1 Pathway Inhibitor NXP800 for Ovarian Cancer
December 3rd 2022The first-in-class Heat Shock Factor 1 pathway inhibitor NXP800, the subject of an ongoing phase 1 dose-escalation study, has been granted a Fast Track designation for the treatment of platinum-resistant ovarian cancer by the FDA.
Additional Studies Needed for Immunotherapy Combinations in Clear Cell Ovarian Carcinoma
October 3rd 2022Despite inconclusive efficacy results regarding the use of pembrolizumab plus epacadostat in patients with recurrent clear cell ovarian carcinoma, rapid accrual to the trial reveals an unmet need in this cancer subset.